Marc L. Mancini v. Commissioner

2019 T.C. Memo. 16
CourtUnited States Tax Court
DecidedMarch 4, 2019
Docket16975-13
StatusUnpublished
Cited by2 cases

This text of 2019 T.C. Memo. 16 (Marc L. Mancini v. Commissioner) is published on Counsel Stack Legal Research, covering United States Tax Court primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Marc L. Mancini v. Commissioner, 2019 T.C. Memo. 16 (tax 2019).

Opinion

T.C. Memo. 2019-16

UNITED STATES TAX COURT

MARC L. MANCINI, Petitioner v. COMMISSIONER OF INTERNAL REVENUE, Respondent

Docket No. 16975-13. Filed March 4, 2019.

Yosef Yisroel Manela, for petitioner.

Paulmikell A. Fabian and Sarah A. Herson, for respondent.

MEMORANDUM FINDINGS OF FACT AND OPINION

HOLMES, Judge: Marc Mancini claims to have lost millions of dollars

gambling. He says the normal limits on gambling-loss deductions shouldn’t apply

to him because his gambling was a side effect of a prescription drug that over a

short time caused him to lose the ability to control his impulses. The -2-

[*2] Commissioner says there’s no proof of that, and even if there is, Mancini

hasn’t substantiated the amounts of his losses or shown that they qualify as

casualty losses.

FINDINGS OF FACT

A. Background

Marc Mancini worked hard and studied hard for many years. He made good

money, saved carefully, and strategically bought Los Angeles real estate. He

gambled occasionally, but only small amounts, and never more than $100 at a

time.

In 2004 Mancini was diagnosed with Parkinson’s disease. He received

treatment from Dr. Mark Lew, a prominent neurologist and professor at the USC

School of Medicine. In 2006 Dr. Lew prescribed Pramipexole (the generic name

for Mirapex), a drug Dr. Lew had given patients in clinical trials even before it had

received Food and Drug Administration (FDA) approval. Dr. Lew initially

prescribed a very small dose for Mancini--0.375 mg a day. He gradually increased

Mancini’s dose, which by 2008 was 4.5 mg a day. The medicine worked, and

Mancini’s symptoms improved significantly.

But in 2008 Mancini started doing odd things. He vacuumed a lot and

became compulsive about his cleanliness. He spent a week researching and -3-

[*3] obsessing over which mattress to buy. He started falling asleep suddenly

while driving. He had suicidal thoughts. And he started gambling--a lot.

At first it was just lottery tickets. Then he started going to casinos--

especially the Venetian in Las Vegas and Morongo near Palm Springs. Then he

moved to online gambling. That’s where he says he suffered his biggest losses,

though he didn’t keep logs of his gambling activity. In 2008 Mancini told Dr.

Lew that he had become still more compulsive and was gambling, but he

minimized the extent of his gambling and said he had it under control.

This was not true. Over the next two years gambling wiped out all of his

bank accounts and all but $10,000 of his retirement savings. In 2009 he also

started selling his real estate for less than fair market value. He first sold a house

he owned in Manhattan Beach to its tenants for a quick $995,000, when he

believed the true value was closer to $1.2 million. Mancini says he liked the

tenants but thinks he would’ve put the house on the open market if he’d been in

his right mind. He also sold property in Massachusetts that he thought was worth

$300,000 for only $90,000. He explained that, with this sale, he felt indebted to

the buyer who had cared for his mother. He used the proceeds from both of these

sales to pay gambling debts. -4-

[*4] In 2010 Mancini’s wife and daughter stepped in. They visited Dr. Lew and

told him that Mancini had gambled away nearly everything he had. This surprised

Dr. Lew because Mancini had told him things were under control. Dr. Lew took

Mancini off Pramipexole, and the compulsive behaviors stopped. Mancini still

gambles occasionally, but only to the limited extent he did before 2008.

B. Pramipexole

Mancini isn’t the only person who’d done weird things while taking

Pramipexole. Pramipexole is a dopamine agonist, meaning it activates dopamine

receptors in the brain. That helps Parkinson’s patients control their movements,

but can also affect the brain’s executive function in a way that distorts risk/reward

assessments. Pramipexole was approved by the FDA in 1997, and by the early

2000s there were reports of users’ developing impulse control disorders (ICDs),

which make sufferers unable to control their behavior despite negative

consequences. The most common ICDs observed among Parkinson’s patients

taking Pramipexole were compulsive eating (Mancini gained about 40 pounds

while on the drug), shopping, or gambling; and hypersexuality. By around 2008

the correlation between Pramipexole and these ICDs was widely accepted. Today

physicians prescribing the drug closely monitor patients for signs that they’re

developing an ICD. -5-

[*5] The incidence of these behaviors is tied to dosage, but not directly--they

don’t tend to occur until the dosage hits a certain level, though they can worsen as

doses are maintained at or above that point. Not everyone on Pramipexole has

these problems, but a major study suggests that the percentage of people who do is

significant: According to the study, dopamine agonist users are 2½ to 3 times

more likely than nonusers to develop an ICD. The ICDs tend to go away once the

patients stop taking Pramipexole, although there can be residual effects.

When the FDA first approved it, Pramipexole didn’t come with warnings

about ICDs in general or gambling in particular. Today, however, it specifically

warns that it can cause compulsive gambling.

C. Pramipexole Lawsuits

Many, many people have sued Pramipexole’s makers over the drug’s side

effects. Hundreds of individual cases have been consolidated into

multijurisdiction litigation in the U.S. District Court for the District of Minnesota.

See In re Mirapex Prods. Liab. Litig., 493 F. Supp. 2d 1376 (J.P.M.L. 2007)

(transferring all Pramipexole cases); In re Mirapex Prods. Liab. Litig., 246 F.R.D.

668, 671 (D. Minn. 2007) (“several hundred” cases pending). One plaintiff who

went to trial in 2008 received a jury verdict for $8.2 million. Charbonneau v.

Boehringer Ingelheim Pharm., Inc., Civil No. 06-1215, Special Verdict (D. Minn. -6-

[*6] July 31, 2008), ECF No. 321. Many other plaintiffs have reached

confidential settlements. See In re Mirapex Prods. Liab. Litig., MDL No. 07-

1836, 2012 WL 6840134, at *1 n.4 (D. Minn. Aug. 3, 2012) (report and

recommendation), adopted in part, rejected in part, 2013 WL 140292 (D. Minn.

Jan. 11, 2013).

Mancini joined such a case in December 2010. The court found that he

should have known about the side effects by April 2008 and dismissed his case

because he hadn’t filed it within California’s two-year statute of limitations. See

Mancini v. Boehringer Ingelheim Pharm., Inc. (In re Mirapex Prods. Liab. Litig.),

Civil No. 10-5009, 2013 WL 1703476 (D. Minn. Feb. 14, 2013) (report and

recommendation); id. 2013 WL 1703510 (D. Minn. Apr. 19, 2013) (order adopting

report and recommendation), aff’d, 912 F.3d 1129 (8th Cir. 2019).

D. Mancini’s Tax Returns

Mancini filed income tax returns while all of this was going on. He filed his

2008 return in October 2009 with the help of a preparer. On it he reported

$149,000 in gambling winnings, deducted $149,000 for “Gambling Losses to

Extent of Winnings,” and claimed no casualty losses. On his 2009 return, which

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Robert G. Taylor, II v. Commissioner
2019 T.C. Memo. 102 (U.S. Tax Court, 2019)

Cite This Page — Counsel Stack

Bluebook (online)
2019 T.C. Memo. 16, Counsel Stack Legal Research, https://law.counselstack.com/opinion/marc-l-mancini-v-commissioner-tax-2019.